What is the 13F Pro Quality Score for DTIL?

13F Pro ranks PRECISION BIOSCIENCES INC (DTIL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DTIL's current score at https://13fpro.ai/company/DTIL (free sign-up required for the full ranking).

Which hedge funds own the most DTIL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DTIL include abrdn plc, Bleichroeder, Octagon Capital Advisors. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/DTIL as soon as new 13F filings post.

Where does 13F Pro source DTIL data?

All PRECISION BIOSCIENCES INC fundamentals and ownership data come directly from SEC EDGAR. PRECISION BIOSCIENCES INC files with the SEC under CIK 1357874. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DTIL in?

PRECISION BIOSCIENCES INC (DTIL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DTIL research updated on 13F Pro?

DTIL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PRECISION BIOSCIENCES INC(DTIL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1357874 DTIL stock profile & AI dashboard →

13F Pro Quality Score

10.6/100

Rank #2,909 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

1.5/100

Profitability

7.3/100

Balance Sheet

5.2/100

Earnings Quality

7.8/100

Free Cash Flow

6.1/100

Institutional Flow

18.4/100

Revenue Scale

7.9/100

Dilution Risk

6.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why DTIL Scores 11/100

exact factor attribution · 2026-09-11

DTIL's composite is driven by earnings growth, held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+2.0 pts

91th pct

Institutional flow

-1.6 pts

18th pct

Shareholder dilution

-2.2 pts

6th pct

Earnings quality

-4.2 pts

8th pct

Capital efficiency

-4.5 pts

5th pct

Scale

-6.3 pts

8th pct

Profitability

-6.4 pts

7th pct

Free cash flow

-6.6 pts

6th pct

Revenue growth

-9.7 pts

2th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

DTIL Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for PRECISION BIOSCIENCES INC (DTIL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DTIL at 10.6/100 on a 32-signal composite quality model, placing it at rank #2,909 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.5) and balance sheet strength (5.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PRECISION BIOSCIENCES INC reports net income of $-32.7M, free cash flow of $-13.4M. Top institutional holders of DTIL by reported 13-F value include abrdn plc, Bleichroeder, Octagon Capital Advisors, based on the most recent SEC filings. DTIL trades on the Nasdaq exchange and files with the SEC under CIK 1357874. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DTIL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PRECISION BIOSCIENCES INC directly from SEC EDGAR. PRECISION BIOSCIENCES INC's 13F Pro composite quality score has ranged between 4 and 58 since 2021, currently 10.6 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about PRECISION BIOSCIENCES INC

Quirks, history, and lore behind DTIL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · small-cap · listed on Nasdaq · headquartered in North Carolina.
2
The Numbers
Revenue is modest — this is a clinical-stage company burning cash in pursuit of breakthroughs, with a market cap that has swung wildly in the hundreds of millions range.
3
The History
Founded in the 2010s, it was built around a proprietary take on genome editing — the hottest corner of biotech — and went public to fund its pipeline.
4
The Secret
Rather than licensing CRISPR from the academic giants, the company developed its own arcus nuclease platform — a distinct gene-editing engine it calls entirely its own.
5
The Lore
Its pipeline spans two ambitious fronts: ex vivo cell therapies for blood cancers and in vivo gene editing delivered directly into the body — essentially rewriting DNA as medicine.
6
The Giveaway
Its ticker spells out DTIL, its name shouts precision, and its Durham lab is quietly trying to edit its way to cures one nuclease cut at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-32.7M

Free Cash Flow

Q2 2026

$-13.4M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-50.1% YoY

$34.3MFY 2025

FY22 $25.1MFY23 $48.7MFY24 $68.7MFY25 $34.3M

Net Income

-738.0% YoY

$-45.7MFY 2025

FY22 $-111.6MFY23 $-61.3MFY24 $7.2MFY25 $-45.7M

Operating Income

-99.3% YoY

$-52.1MFY 2025

FY22 $-62.3MFY23 $-43.7MFY24 $-26.2MFY25 $-52.1M

EPS (Diluted)

-784.6% YoY

$-3.56FY 2025

FY22 $-0.64FY23 $-0.27FY24 $0.52FY25 $-3.56

Total Assets

+13.2% YoY

$154.4MFY 2025

FY22 $238.2MFY23 $159.8MFY24 $136.4MFY25 $154.4M

Total Debt

—FY 2025

FY22 $22.2MFY23 —FY24 —FY25 —

Op. Cash Flow

-12.7% YoY

$-65.8MFY 2025

FY22 $-45.8MFY23 $-84.1MFY24 $-58.4MFY25 $-65.8M

Free Cash Flow

-12.3% YoY

$-65.9MFY 2025

FY22 $-49.1MFY23 $-86.1MFY24 $-58.7MFY25 $-65.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$34.3M -50.1%	$68.7M +41.0%	$48.7M +94.1%	$25.1M -78.3%	$115.5M +375.7%	$24.3M
Net Income	$-45.7M -738.0%	$7.2M +111.7%	$-61.3M +45.1%	$-111.6M -264.8%	$-30.6M +71.9%	$-109.0M
Operating Income	$-52.1M -99.3%	$-26.2M +40.2%	$-43.7M +29.8%	$-62.3M -58.2%	$-39.4M +64.1%	$-109.8M
EPS (Diluted)	$-3.56 -784.6%	$0.52 +295.5%	$-0.27 +58.1%	$-0.64 -143.9%	$-0.26	—
Total Assets	$154.4M +13.2%	$136.4M -14.6%	$159.8M -32.9%	$238.2M +12.6%	$211.5M +40.9%	$150.2M
Total Debt	—	—	—	$22.2M +796.8%	$2.5M	—
Operating Cash Flow	$-65.8M -12.7%	$-58.4M +30.5%	$-84.1M -83.8%	$-45.8M -321.6%	$-10.9M +87.6%	$-87.4M
Free Cash Flow	$-65.9M -12.3%	$-58.7M +31.8%	$-86.1M -75.4%	$-49.1M -208.5%	$-15.9M +82.8%	$-92.4M

Get alerted when DTIL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PRECISION BIOSCIENCES INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DTIL

abrdn plc
$17.5M2,230,178 sh
Bleichroeder LP
$15.9M2,018,190 sh
Octagon Capital Advisors LP
$10.6M1,350,000 sh
BOOTHBAY FUND MANAGEMENT, LLC
$10.6M1,346,004 sh
BlackRock, Inc.
$9.2M1,172,873 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.8M1,116,241 sh
Lynx1 Capital Management LP
$7.5M950,466 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$7.4M946,707 sh
Empery Asset Management, LP
$6.1M776,093 sh
Affinity Asset Advisors, LLC
$5.1M646,576 sh

Fund	Value	Shares
abrdn plc	$17.5M	2,230,178
Bleichroeder LP	$15.9M	2,018,190
Octagon Capital Advisors LP	$10.6M	1,350,000
BOOTHBAY FUND MANAGEMENT, LLC	$10.6M	1,346,004
BlackRock, Inc.	$9.2M	1,172,873
VANGUARD CAPITAL MANAGEMENT LLC	$8.8M	1,116,241
Lynx1 Capital Management LP	$7.5M	950,466
DRIEHAUS CAPITAL MANAGEMENT LLC	$7.4M	946,707
Empery Asset Management, LP	$6.1M	776,093
Affinity Asset Advisors, LLC	$5.1M	646,576

Companies Similar to DTIL

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

AVTX

Avalo Therapeutics, Inc.

AI score

Very similar · 6 shared holders

Affinity Asset Advisors, LLC abrdn plc Velan Capital Investment Management LP

XNCR

Xencor Inc

AI score

Very similar · 4 shared holders

Velan Capital Investment Management LP Lynx1 Capital Management LP Susquehanna Portfolio Strategies, LLC

DNTH

Dianthus Therapeutics, Inc. /DE/

AI score

Similar quality profile · 6 shared holders

Octagon Capital Advisors LP DRIEHAUS CAPITAL MANAGEMENT LLC Affinity Asset Advisors, LLC

SERA

SERA PROGNOSTICS, INC.

AI score

Similar quality profile · 2 shared holders

abrdn plc Vivo Capital, LLC

TSHA

Taysha Gene Therapies, Inc.

AI score

Similar quality profile · 5 shared holders

abrdn plc Octagon Capital Advisors LP Affinity Asset Advisors, LLC

GOSS

Gossamer Bio, Inc.

AI score

Similar quality profile · 3 shared holders

Octagon Capital Advisors LP Velan Capital Investment Management LP China Universal Asset Management Co., Ltd.

NRIX

Nurix Therapeutics, Inc.

AI score

Similar quality profile · 6 shared holders

Affinity Asset Advisors, LLC ArrowMark Colorado Holdings LLC Velan Capital Investment Management LP

VRCA

Verrica Pharmaceuticals Inc.

AI score

Similar quality profile · 4 shared holders

Affinity Asset Advisors, LLC Velan Capital Investment Management LP Stonepine Capital Management, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DTIL on your watchlist

Track score changes the day PRECISION BIOSCIENCES INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DTIL a good stock to buy?

13F Pro's AI-powered analysis of PRECISION BIOSCIENCES INC (DTIL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DTIL are available on the DTIL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DTIL is classified as a small company.

Which hedge funds own DTIL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DTIL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PRECISION BIOSCIENCES INC's investment landscape.